SCHEMBL4348545

SCHEMBL4348545

CCN(CC)C1=NC(=O)C(=Cc2ccc(C)cc2)S1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.58
MEN1 O00255 1/20 0.58
NPC1 O15118 1/20 0.58
TNNI3 P19429 1/20 0.58
TNNT2 P45379 1/20 0.58
GFER P55789 1/20 0.58
TNNC1 P63316 1/20 0.58
KMT2A Q03164 1/20 0.58
POLB P06746 1/20 0.54
ALOX5 P09917 12/20 0.51
MAPT P10636 1/20 0.51
MYC P01106 1/20 0.47
MAX P61244 1/20 0.47
PIM1 P11309 1/20 0.45
HPGD P15428 1/20 0.45
PIM2 Q9P1W9 1/20 0.45
PRMT5 O14744 1/20 0.45
PRMT1 Q99873 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4348541 1.00 RAB9A (0.58) RAB9AMEN1NPC1TNNI3TNNT2
Bromide SCHEMBL4348012 0.99 RAB9A (0.56) RAB9AMEN1NPC1TNNI3TNNT2
Bromide SCHEMBL4348013 0.99 RAB9A (0.56) RAB9AMEN1NPC1TNNI3TNNT2
SCHEMBL4348986 0.87 MEN1 (0.56) RAB9AMEN1NPC1TNNI3TNNT2
SCHEMBL4348992 0.87 MEN1 (0.56) RAB9AMEN1NPC1TNNI3TNNT2
SCHEMBL4350157 0.87 POLB (0.71) RAB9AMEN1NPC1TNNI3TNNT2
SCHEMBL4350154 0.87 POLB (0.71) RAB9AMEN1NPC1TNNI3TNNT2
Bromide SCHEMBL4357393 0.86 MEN1 (0.55) RAB9AMEN1NPC1TNNI3TNNT2
SCHEMBL14589646 0.86 MEN1 (0.62) RAB9AMEN1NPC1TNNI3TNNT2
Bromide SCHEMBL4357396 0.86 MEN1 (0.55) RAB9AMEN1NPC1TNNI3TNNT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP claimed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US claimed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP claimed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO claimed
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP disclosed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US disclosed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP disclosed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs ABCB1, ABCG2, SLC5A2 RAB9A 3151/4885MEN1 1725/4885NPC1 326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.